HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing

HBV Enhances Sorafenib Resistance in Hepatocellular Carcinoma by Reducing Ferroptosis via SRSF2-Mediated Abnormal PCLAF Splicing

Hepatocellular carcinoma (HCC) is one of the most lethal human cancers. Hepatitis B virus (HBV) infection accounts for nearly 50% of HCC cases. Recent studies indicate that HBV infection induces resistance to sorafenib, the first-line systemic treatment for advanced HCC for more than a decade, from...

Full description

Bibliographic Details
Main Authors: Lijuan Liu, Zhao Lv, Miao Wang, Dongyan Zhang, Dongying Liu, Fan Zhu
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
hepatitis B virus (HBV)
hepatocellular carcinoma (HCC)
alternative splicing
proliferating cell nuclear antigen clamp-associated factor (PCLAF)
sorafenib resistance
ferroptosis
Online Access:https://www.mdpi.com/1422-0067/24/4/3263

Internet

https://www.mdpi.com/1422-0067/24/4/3263

Similar Items